NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Cambrian Bio

Cambrian Bio

Private
New York City, New YorkHealthcare & Life Scienceshttp://ww25.cambrian.bio/?subid1=20251210-1246-4735-8194-d5d904c93c24

Last Round

Series C

Oct 26, 2021

Est. Valuation

$497M

Total Funding Raised

$141M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Cambrian Bio is a biotechnology and venture capital company that builds, finances, and manages a portfolio of companies developing therapeutics for age-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine, Biotech Equipment

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

age-related disease therapeuticsdistributed development companyDisCohealthspan extensionlongevity biotechanti-aging medicinehub-and-spoke biotechdrug development portfolioclinical-stage biotechdrivers of agingbiotech venture buildergerosciencedrug licensingAMPK activatormTOR inhibitorstelomere lengtheningcell therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cambrian Bio Comparables

Compare Cambrian Bio with similar companies based on industry and business-model similarity.

Cambrian Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Cambrian Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series COct 26, 2021
VC RoundFeb 9, 2021
UnknownJan 17, 2020

Key People

Founding team and executive leadership

James Peyer

Founder CEO

Founding Team

Cambrian Bio Investors

Notable investors and investment history

Cambrian Bio investors
InvestorRounds
Future VenturesSeries C, Unknown, VC Round
Galaxy DigitalVC Round, Unknown
SALTSeries C
Lux CapitalSeries C
Catalio Capital ManagementUnknown, VC Round
Apeiron Investment GroupSeries C, Unknown, VC Round
Infinitas CapitalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 25, 2026

    TOR-101 asset is in IND-enabling development for clinical studies.

  • Mar 25, 2026

    ATX-304 is advancing through clinical trials for obesity treatment.

Cambrian Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cambrian Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cambrian Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range30
Year Founded2019
Last FundingOct 26, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.